1246960-27-9

Evogliptin(DA-1229) is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) that can improve insulin resistance and delays the onset of diabetes. Evogliptin delays the onset of diabetes in young db/db mice and improves insulin sensitiv

Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity.

Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes signals by inducing autophagy. Evogliptin can be used to study type 2 diabetes, chronic liver inflammation, osteoporosis and renal impairment.